# Agenus Inc. clinical trials: 31 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials with Agenus Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Agenus Inc.: 31 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/agenus-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 30, 2024 | NCT06751524 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval | Agenus Inc. | Not applicable | Available | Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC)... | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06751524) |
| November 29, 2022 | NCT05630183 | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | Agenus Inc. | Phase 2 | Completed | Metastatic Pancreatic Ductal Adenocarcinoma | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05630183) |
| November 8, 2022 | NCT05608044 | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Agenus Inc. | Phase 2 | Active not recruiting | Metastatic Colorectal Cancer | 234 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05608044) |
| October 10, 2022 | NCT05572970 | Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884) | Agenus Inc. | Not applicable | Available | Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05572970) |
| September 7, 2022 | NCT05529316 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | Agenus Inc. | Phase 2 | Terminated | Advanced Melanoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05529316) |
| May 17, 2022 | NCT05377528 | Study of AGEN1571 in Participants With Advanced Solid Tumors | Agenus Inc. | Phase 1 | Completed | Advanced Solid Tumor | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05377528) |
| September 2, 2021 | NCT05033132 | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer | Agenus Inc. | Phase 2 | Withdrawn | Cervical Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05033132) |
| August 27, 2021 | NCT05025085 | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors | Agenus Inc. | Phase 1 | Completed | Advanced Cancer | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05025085) |
| June 29, 2021 | NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | Agenus Inc. | Phase 3 | Withdrawn | Advanced Cancer, Metastatic Cervical Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04943627) |
| October 29, 2020 | NCT04607200 | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma | Agenus Inc. | Phase 2 | Withdrawn | Angiosarcoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04607200) |
| November 7, 2019 | NCT04156100 | A Study in Subjects With Advanced Solid Tumors | Agenus Inc. | Phase 1 | Terminated | Advanced Solid Tumor | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04156100) |
| October 10, 2019 | NCT04121676 | Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer | Agenus Inc. | Phase 1 | Completed | Advanced Cancer | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04121676) |
| March 28, 2019 | NCT03894215 | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer | Agenus Inc. | Phase 2 | Terminated | Cervical Cancer | 211 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03894215) |
| March 1, 2019 | NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | Agenus Inc. | Phase 1 | Active not recruiting | Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma... | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03860272) |
| September 17, 2018 | NCT03673020 | Phase 1a Study to Evaluate Immunogenicity of ASV® | Agenus Inc. | Phase 1 | Completed | Solid Tumor, Adult | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03673020) |
| April 12, 2018 | NCT03495882 | A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into... | Agenus Inc. | Phase 1/2 | Completed | Cervical Cancer | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03495882) |
| January 26, 2018 | NCT03411473 | Study of AGEN1884 With Pembrolizumab in 1L NSCLC | Agenus Inc. | Phase 2 | Terminated | NSCLC Stage IV | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03411473) |
| April 7, 2017 | NCT03104699 | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer | Agenus Inc. | Phase 1/2 | Completed | Advanced Cancer, Cervical Cancer | 211 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03104699) |
| December 14, 2016 | NCT02992977 | Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer | Agenus Inc. | Phase 1 | Terminated | Advanced Cancer | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02992977) |
| March 1, 2016 | NCT02694822 | AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With... | Agenus Inc. | Phase 1/2 | Completed | Advanced Solid Cancers, Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02694822) |
| September 19, 2012 | NCT01687595 | Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes | Agenus Inc. | Phase 2 | Completed | Herpes Simplex Type 2 | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01687595) |
| June 22, 2010 | NCT01147536 | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at... | Agenus Inc. | Phase 2 | Terminated | Renal Cell Carcinoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01147536) |
| April 21, 2006 | NCT00316511 | Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma | Agenus Inc. | Phase 1 | Completed | Malignancies, B-Cell Lymphoma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00316511) |
| October 4, 2005 | NCT00231049 | Trial Evaluating Safety, Tolerability and Immune Response of AG-707 | Agenus Inc. | Phase 1 | Completed | Genital Herpes | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00231049) |
| August 3, 2005 | NCT00126178 | Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer | Agenus Inc. | Phase 3 | Terminated | Kidney Cancer, Renal Cell Carcinoma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00126178) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 9 |
| Phase 1/2 | 3 |
| Phase 2 | 13 |
| Phase 3 | 4 |
| Not applicable | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 15 |
| Terminated | 9 |
| Withdrawn | 3 |
| Available | 2 |
| Active not recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 6 |
| Uterine Cervical Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Carcinoma, Renal Cell | 4 |
| Melanoma | 3 |
| Kidney Neoplasms | 3 |
| Herpes Genitalis | 2 |
| Colorectal Neoplasms | 2 |
| Hemangiosarcoma | 2 |
| Ovarian Neoplasms | 2 |
| Prostatic Neoplasms | 2 |
| Lymphoma, B-Cell | 1 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 |
| Skin Neoplasms | 1 |
| Parkinson Disease 4, Autosomal Dominant Lewy Body | 1 |
| Diabetes Mellitus, Insulin-Dependent, 12 | 1 |
| Lymphoma, Follicular | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Lymphoma, B-Cell, Marginal Zone | 1 |
| Waldenstrom Macroglobulinemia | 1 |
| Endometrial Neoplasms | 1 |
| Fibrolamellar hepatocellular carcinoma | 1 |
| Lung Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Acupuncture clinics in the United States](https://specstream.ai/data/businesses/acupuncture-clinics/united-states)
- [Bathtub and sink repair companies in the United States](https://specstream.ai/data/businesses/bathtub-and-sink-repair-companies/united-states)
- [Contract law firms in the United States](https://specstream.ai/data/businesses/contract-law-firms/united-states)
- [Fabric wholesalers in the United States](https://specstream.ai/data/businesses/fabric-wholesalers/united-states)
- [Hotels in the United States](https://specstream.ai/data/businesses/hotels/united-states)
- [Medical billing companies in the United States](https://specstream.ai/data/businesses/medical-billing-companies/united-states)
